OncoMatch/Clinical Trials/NCT06503263
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Is NCT06503263 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zanubrutinib plus Lenalidomide as Maintenance Therapy for diffuse large b-cell lymphoma.
Treatment: Zanubrutinib plus Lenalidomide as Maintenance Therapy — The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: chemotherapy — induction
Patient has recieved complete remission and has completed planed courses of chemotherapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (≥ 1 x 10^9/L if bone marrow involvement by lymphoma); Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL
Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10^9/L (≥ 1 x 10^9/L if bone marrow (BM) involvement by lymphoma)；Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma)； Hemoglobin ≥ 8 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify